Satellos Bioscience Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
368.2M
P/E Ratio
5.09
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Healthcare
Biotechnology
TSX
Key Financial Metrics
-
Revenue
-19.6M
Net Income
C$2.09
EPS (Diluted)
-17.4M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-19.6M
Returns & Efficiency
Return on Assets (ROA)
-38.5%
Return on Equity (ROE)
-41.4%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
50.9M
Total Debt
-
Debt to Equity
-
Current Ratio
14.16
Company Info
| Industry | Biotechnology |
| HQ | Toronto, Canada |
| Employees | 14 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | satellos.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
36,069,256
Shares Sold
0
Total Transactions
14
SEDAR+ Filings
View All Filings5
Annual Reports
14
Quarterly Reports
17
MD&A
57
News Releases
3
Material Changes
2
Prospectuses
9
Governance
37
Certifications
36
Other
●
2021-04-29
●
2020-05-15
●
2018-07-23
●
2018-07-23
●
2018-07-23
●
2021-08-17
●
2021-05-07
●
2019-08-21
●
2018-08-14
●
2018-08-07
Interactive Charts
Company Profile
General Information
| Company Name | Satellos Bioscience Inc. |
| Ticker | MSCL.TO |
| Exchange | TSX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Toronto, Canada |
| Employees | 14 |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | satellos.com |
Financial Summary
| Market Cap | 368.2M |
| Revenue | N/A |
| Net Income | -19.6M |
| P/E Ratio | 5.09 |
| EPS (Diluted) | C$2.09 |
| Net Margin | N/A |
| ROE | -41.4% |
| Dividend Yield | N/A |
Business Description
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.